Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Effect of piglitazone and metformin on retinol-binding protein-4 and adiponectin in patients with type 2 diabetes mellitus complicated with non-alcohol fatty acid liver diseases.

Yang L, Song MQ, Zhang QL, Shou L, Zang SF, Yang YL.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2014 Jun;36(3):309-12. doi: 10.3881/j.issn.1000-503X.2014.03.015.

2.

Role of APN and TNF-α in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease.

Lin X, Zhang Z, Chen JM, Xu YY, Ye HR, Cui J, Fang Y, Jin Y, Zhu DR, Yuan L.

Genet Mol Res. 2015 Apr 10;14(2):2940-6. doi: 10.4238/2015.April.10.1.

3.

Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.

Kadoglou NP, Kapelouzou A, Tsanikidis H, Vitta I, Liapis CD, Sailer N.

Exp Clin Endocrinol Diabetes. 2011 Feb;119(2):63-8. doi: 10.1055/s-0030-1265174. Epub 2010 Oct 28.

PMID:
21031343
4.

Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients.

Koh JH, Shin YG, Nam SM, Lee MY, Chung CH, Shin JY.

Diabetes Care. 2009 Jan;32(1):147-52. doi: 10.2337/dc08-1379. Epub 2008 Oct 3.

5.

Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.

Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P.

Clin Endocrinol (Oxf). 2006 Dec;65(6):722-8.

PMID:
17121522
6.

Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.

Wu H, Jia W, Bao Y, Lu J, Zhu J, Wang R, Chen Y, Xiang K.

Diabetes Res Clin Pract. 2008 Feb;79(2):185-90. Epub 2007 Sep 29.

PMID:
17904683
7.

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.

Metabolism. 2010 Jun;59(6):887-95. doi: 10.1016/j.metabol.2009.10.007. Epub 2009 Dec 16.

PMID:
20015525
8.

The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease.

Nar A, Gedik O.

Acta Diabetol. 2009 Jun;46(2):113-8. doi: 10.1007/s00592-008-0067-2. Epub 2008 Oct 7.

PMID:
18839053
9.

The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.

Erdem G, Dogru T, Tasci I, Bozoglu E, Muhsiroglu O, Tapan S, Ercin CN, Sonmez A.

Diabetes Res Clin Pract. 2008 Nov;82(2):214-8. doi: 10.1016/j.diabres.2008.07.021. Epub 2008 Sep 7.

PMID:
18778865
10.

Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver.

Shaker O, El-Shehaby A, Zakaria A, Mostafa N, Talaat S, Katsiki N, Mikhailidis DP.

Clin Biochem. 2011 Dec;44(17-18):1457-63. doi: 10.1016/j.clinbiochem.2011.08.1148. Epub 2011 Sep 12.

PMID:
21939650
11.

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease.

Fan H, Pan Q, Xu Y, Yang X.

Arq Bras Endocrinol Metabol. 2013 Dec;57(9):702-8.

12.

Serum retinal-binding protein 4 is positively related to insulin resistance in Chinese subjects with type 2 diabetes.

Cheng X, Zhang H.

Diabetes Res Clin Pract. 2009 Apr;84(1):58-60. doi: 10.1016/j.diabres.2009.01.007. Epub 2009 Feb 4.

PMID:
19195734
13.
14.

The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus.

Jung HS, Youn BS, Cho YM, Yu KY, Park HJ, Shin CS, Kim SY, Lee HK, Park KS.

Metabolism. 2005 Mar;54(3):314-20.

PMID:
15736108
15.
16.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
17.

Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.

Xu P, Zhang XG, Li YM, Yu CH, Xu L, Xu GY.

J Zhejiang Univ Sci B. 2006 Aug;7(8):627-33.

18.

Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats.

Qi Z, Xue J, Zhang Y, Wang H, Xie M.

Planta Med. 2011 Feb;77(3):231-5. doi: 10.1055/s-0030-1250268. Epub 2010 Aug 17.

PMID:
20717873
19.

[Change and correlated factors of fasting level of the plasma endotoxin in subjects with different glucose tolerances and body mass indices].

Liu YH, Zhao TY, Hou LQ.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2013 Sep;44(5):769-73, 778. Chinese.

PMID:
24325109
20.

Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.

Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M.

Obesity (Silver Spring). 2011 Dec;19(12):2310-5. doi: 10.1038/oby.2011.152. Epub 2011 Jun 9.

Supplemental Content

Support Center